drugset

drugset / Trial / NCT00726115

Study Evaluating Safety, Tolerability and Pharmacokinetics of Single and Multiple Dose of SAM-531

NCT00726115 ↗

Phase 1 Completed 56 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

The main objectives of this study is to assess the safety and tolerability of ascending single and multiple oral doses of SAM-531 in healthy subjects

Timeline

Start: 2008-08
Primary completion: 2009-02
Completion: 2009-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	CERLAPIRDINE	Small molecule	—	—

Indications